Avenue Therapeutics, INC. (ATXI) — 10-Q Filings

All 10-Q filings from Avenue Therapeutics, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

ATXI Narrows Losses Amid Nasdaq Delisting, AnnJi Deal Termination — Nov 13, 2025 Risk: high
AVENUE THERAPEUTICS, INC. (ATXI) reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $2.221 million from $1
Avenue Therapeutics Swings to Profit on AnnJi Deal, Faces Going Concern Doubts — Aug 14, 2025 Risk: high
Avenue Therapeutics, Inc. reported a net income of $335,000 for the three months ended June 30, 2025, a significant improvement from a net loss of $2.692 millio
Avenue Therapeutics Files Q1 2025 10-Q with Minimal Financial Activity — May 15, 2025 Risk: medium
Avenue Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal financial activity for the first quarter of 2025, wi
Avenue Therapeutics Q3 2024: Minimal Financial Activity — Nov 14, 2024 Risk: medium
Avenue Therapeutics, Inc. filed its Q3 2024 10-Q report on November 14, 2024, for the period ending September 30, 2024. The company reported minimal financial a
Avenue Therapeutics Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
Avenue Therapeutics, Inc. filed its Q2 2024 10-Q report on August 9, 2024, for the period ending June 30, 2024. The company's financial statements show minimal

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX